A new study published in Nature’s Scientific Reports reveals that an artificial intelligence (AI) algorithm developed by Tel Aviv-based Fairtility could significantly increase the success rates of in vitro fertilization (IVF). IVF is a medical procedure where eggs are surgically removed from the ovary and mixed with sperm in a laboratory. After a few days, an embryologist selects the highest-potential blastocyst, a very early-stage embryo, to be implanted in the uterus.
Currently, the chances of a successful live birth through a single IVF procedure are less than half for women under the age of 35 and less than 10% for women in their early 40s. However, Fairtility’s AI decision-support software platform, CHLOE, has shown promising results in improving the accuracy and speed of embryo assessment compared to embryologists.
Dr. Iris Har Vardi, Fairtility’s scientific adviser and director of the Fertility and IVF Lab at Soroka University Medical Center, explained that CHLOE allowed them to measure various embryo components automatically with higher accuracy and speed. The study used CHLOE to retrospectively assess the implantation potential of 608 blastocysts selected for IVF using standard criteria. The researchers discovered that slightly larger blastocysts had a higher likelihood of successful implantation.
The study, led by Yael Fruchter-Goldmeier and Ben Kantor from Ben-Gurion University, is the first to establish a correlation between automatically measured blastocyst morphometric parameters and implantation. The use of AI technology in blastocyst selection has the potential to enhance the effectiveness and personalization of reproductive healthcare.
Fairtility’s CHLOE products are already used in multiple IVF clinics worldwide for automated embryo quality assessment and other fertility-related assessments. The software could not only improve patient care but also provide new insights for treatment decisions and advance the field of reproductive medicine.
According to Eran Eshed, CEO of Fairtility, leveraging AI technologies can uplift care in clinics and continue to contribute to the advancement of reproductive healthcare in the long term.
Sources:
– Nature’s Scientific Reports
– Fairtility
– Dr. Iris Har Vardi, Scientific Adviser at Fairtility and Director of the Fertility and IVF Lab at Soroka University Medical Center
– Yael Fruchter-Goldmeier and Ben Kantor, Ben-Gurion University
– Society for Assisted Reproductive Technology
